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Tuberculous meningitis (TBM) remains a major cause of death and disability in tuberculosis-endemic areas, especially in young chil-
dren and immunocompromised adults. Research aimed at improving outcomes is hampered by poor standardization, which limits 
study comparison and the generalizability of results. We propose standardized methods for the conduct of TBM clinical research 
that were drafted at an international tuberculous meningitis research meeting organized by the Oxford University Clinical Research 
Unit in Vietnam. We propose a core dataset including demographic and clinical information to be collected at study enrollment, 
important aspects related to patient management and monitoring, and standardized reporting of patient outcomes. The criteria 
proposed for the conduct of observational and intervention TBM studies should improve the quality of future research outputs, can 
facilitate multicenter studies and meta-analyses of pooled data, and could provide the foundation for a global TBM data repository.
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Tuberculous meningitis (TBM) was almost universally fatal 
until the first antibiotic treatment with streptomycin and iso-
niazid became available [1]. TBM remains a major cause of 
disease, disability, and death in tuberculosis-endemic areas, but 
research aimed at improving outcomes is hampered by difficul-
ties in patient recruitment and heterogeneous research meth-
odology. The development of a consensus TBM case definition 
for use in TBM research has assisted new diagnostic studies by 
providing a uniform reference standard [2]. However, variable 
data collection methods, different disease classification systems, 
and the absence of standardized outcome assessment continue 
to limit study comparison and complicate efforts to perform 
systematic reviews and meta-analyses.
The need to standardize clinical trial endpoints is well recognized 
for pulmonary and drug-resistant tuberculosis research and is the 
focus of several international consortia (eg, PreDICT-TB [www.
predict-tb.eu], RESIST-TB [www.resisttb.org], and TREAT-TB 
[www.treattb.org]). Core research methods have been proposed 
for adults and children with multidrug-resistant tuberculosis [3, 
4]. In this context, the Oxford University Clinical Research Unit 
in Vietnam, together with the University of Cape Town’s Clinical 
Infectious Diseases Research Initiative, organized a meeting of 
international TBM researchers in Dalat, Vietnam (20–22 May 
2015) to assess recent progress and address key challenges in TBM 
research. Researchers actively engaged in TBM research worldwide 
were invited with the aim of creating an international consortium 
that could make recommendations concerning the objectives and 
methodology of future TBM clinical research.
A TBM research methodological framework was discussed and 
agreed upon during the meeting by all delegates, broadly defin-
ing the key baseline, treatment, and outcome data required in 
the conduct of TBM research. Thereafter, proposed essential and 
desirable data were circulated by the lead authors (B. J. M., A. D. 
H., and G. E. T.) and agreed or adapted by the writing committee 
(all listed authors) until consensus was found. A statement thereby 
arose from the meeting, proposing standardized criteria for the 
conduct and reporting of TBM research and shared data collec-
tion templates. We provide an overview of the consensus reached 
by the consortium, identifying demographic and clinical informa-
tion to be collected at study enrollment, important aspects related 
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to patient management and monitoring, and standardized report-
ing of patient outcomes. Specific data points were categorized as 
either essential or desirable. The essential data points are intended 
to define minimum criteria for the conduct of both observational 
and intervention studies, and to identify a core dataset for uni-
versal use in future clinical research. Better-harmonized research 
methods would improve the quality of research outputs and facil-
itate study comparisons and, in the future, may provide the foun-
dation for a global TBM data repository.
COHORT DESCRIPTION AND METHODS
Adequate cohort description with clarification of the clinical 
“point of entry” is essential to ensure study reproducibility and 
to interrogate differences in study outcomes that may be unre-
lated to the intervention studied. Because treatment outcomes 
and diagnostic test performance may vary according to the 
severity of disease, age, immune status, and patient manage-
ment, the study population must be well characterized in terms 
of setting, inclusion criteria, demographics, human immuno-
deficiency virus (HIV) infection and immune status, disease 
classification, and treatment received.
INFORMATION TO COLLECT AT ENROLLMENT
Table 1 provides a summary of essential and desirable base-
line information to be collected at study enrollment. Essential 
data points include information required by the previously 
published uniform TBM research case definition (Table  2) 
[2], which should be applied to ensure adequate diagnostic 
workup and to characterize the study cohort in a standard-
ized fashion. For diagnostic studies, it is important to ensure 
that control subjects represent a credible clinical entry point 
for TBM diagnostic evaluation, to assess “real-life” diagnostic 
accuracy.
Disease Severity and Phenotype
Given the diversity of clinical presentation and disease sever-
ity, it is important to grade TBM severity in a pragmatic and 
standardized fashion. As a minimum, HIV status (preferably 
with CD4 count and World Health Organization [WHO] clini-
cal disease staging) must be recorded and the modified British 
Medical Research Council (BMRC) TBM grade should be 
ascertained in all studied patients before the start of treatment. 
BMRC investigators [1] first graded TBM patients as “early” (no 
clinical signs of meningitis or focal neurology and fully con-
scious); “medium” (patient’s condition falling between early and 
advanced); and “advanced” (extremely ill, in deep coma). With 
the introduction of the Glasgow Coma Scale (GCS) in 1974 [5], 
this was modified as grade I (GCS 15; no focal neurological 
signs), grade II (GCS 11–14, or 15 with focal neurological signs), 
and grade III (GCS ≤10) disease [6]. Numerous studies across 
all age groups have shown that the modified BMRC grade is a 
strong independent predictor of outcome [6–10]. TBM patients 
with grade I disease are often underrepresented in studies, as 
their nonspecific symptoms may not trigger a lumbar punc-
ture, which usually provides the entry point for TBM studies. 
Subdivision of grade II disease has been proposed [11], as have 
other prognostic systems based on weighted scoring of mental 
status, seizures, cranial nerve palsies, motor deficit, and tone 
[12], but these have not been validated. Because level of con-
sciousness is influenced by rapidly reversible raised intracranial 
pressure and electrolyte disturbances, it is important to repeat 
the BMRC disease severity grading 7 days after TBM treatment 
initiation. This provides a useful reassessment of disease sever-
ity that may be better associated with long-term outcome than a 
single baseline assessment.
Baseline Investigations
Essential and desired study investigations, to be performed at 
enrollment, are summarized in Table  1. Cerebrospinal fluid 
(CSF) sampling and analysis are essential to assist diagnostic 
workup and cohort description and to define prognosis. Low 
CSF white blood cell count, low glucose, and high lactate have 
been associated with death in studies from Vietnam [13]. In 
HIV-coinfected patients, baseline CSF neutrophil count and 
culture positivity for Mycobacterium tuberculosis are predic-
tive of TBM immune reconstitution inflammatory syndrome 
(IRIS) [14]. Cryptococcal meningitis and TBM have similar 
presenting features and CSF cryptococcal antigen tests should 
be performed, especially in those with advanced HIV infec-
tion (peripheral CD4+ count  <100 cells/µL), in whom both 
diseases are common. Peripheral blood findings have limited 
diagnostic or prognostic value, but it is important to document 
anemia, determine baseline renal and liver function tests for 
drug toxicity monitoring, and assess HIV and immune status. 
Hyponatremia has been linked to a worse outcome [15], while 
in HIV-1–coinfected patients lower blood hematocrit [13] and 
low CD4+ T-cell count [16, 17] have been associated with death.
Brain computed tomography (CT) with or without contrast 
and magnetic resonance imaging (MRI) characterize the patho-
logical processes underlying the clinical presentation, disease 
course, and long-term consequences of TBM. Baseline brain 
imaging is recommended for all patients, although this may not 
be available in all settings [18]. Classic imaging findings include 
basal meningeal enhancement, hydrocephalus, tuberculomas, 
and cerebral infarction [19]. MRI is more sensitive in detecting 
early ischemia and brainstem lesions [20]. TBM-related infarcts 
are most commonly located in the territories of the proximal 
middle cerebral artery and the medial lenticulostriate and 
thalamoperforating vessels [21, 22]. Brain imaging provides 
a window on the pathophysiology of TBM, and standardized 
documentation of these complications and their response to 
treatment could improve management and may suggest new 
therapeutic approaches.
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Sample Collection and Laboratory Methods
Diagnostic yield is influenced by both the type and quality 
of specimens collected; therefore careful description of spec-
imen collection methods and test procedures are important. 
Microbiological yield is affected by CSF volume, sample 
transport delays, and processing techniques [23]. The CSF 
sample volume used for each mycobacterial diagnostic test 
should be reported. In addition, adequate quality assur-
ance of all research laboratories is essential to ensure test 
reliability.
Table 1. Baseline Information to Be Collected at Enrollment in Tuberculous Meningitis Studies
Information Essential Desirable
Demographics Age (date of birth)
Sex
Nationality, ethnicity
Medical facility
Presenting symptoms Neurological symptoms (headache, vomiting, 
convulsions)—durationa
Systemic symptoms (weight loss, night sweats, cough, 
fever)—durationa
Medical history Previous and/or current TB
Previous TB preventive therapy
HIV infection/ART
Diabetes (use of insulin)
In children
 BCG vaccination/scar
 Recent TB contacta,b
Number of previous TB episodes; date most recent treatment/ 
preventive therapy; regimen used; adherence
History of intravenous drug use
BCG vaccination/scar (adults)
Clinical findings Weight (true or estimated)
Glasgow Coma Scale scorea
Cranial nerve palsy or other focal neurological deficit (specify)a
In children
 Modified Glasgow Coma Scale for infants
 Head circumference (<5 y)
 Weight and failure to thrive
Height
Neck stiffness
Convulsions (focal or generalized)
Papilledema or other signs of raised intracranial pressure
Laboratory investigations CSF
 Appearancea
 Total and differential WBC counta
 Protein and glucosea
 India ink stain (and/or cryptococcal antigen)a
 Mycobacterial culture (and/or NAAT) and drug susceptibility 
testinga,d
Extraneural samples
 ZN staina; Mycobacterial culture (and/or NAAT)a,d
Peripheral blood
 FBC with differential WBC count
 Plasma glucose (paired with CSF), sodium, potassium, urea, 
and creatinine
 Liver aminotransferases (AST, ALT baseline)
 HIV test (if not known to be positive)
In children
 TST and/or IGRAa
CSF
 Collection site (lumbar, ventricular)
 Volume (for TB investigations)
 ZN stainc
 Lactate 
 Opening pressure
 Additional tests to exclude alternative diagnoses (eg, bacterial 
and fungal culture, enterovirus PCR)
 IGRA or TST (adults)
 Hepatitis B or C coinfection
 Syphilis serology
Imaging Chest radiograph
Signs of active TBa; miliary appearance
Brain CT or MRIa
Hydrocephalus; basal meningeal enhancement, infarct, 
tuberculoma
Imaging (MRI/CT/ultrasound) of extraneural sites suspected of TB 
diseasea
Air encephalogram to differentiate communicating and noncom-
municating hydrocephalus
Hydrocephalus description; presence of periventricular edema; 
herniation
Infarct; type; single/multiple; anatomical location
Diagnostic certainty and 
disease severity
Definite, probable, possible or not TBMa
BMRC TBM severity gradee (1, 2, or 3)
If HIV infected WHO clinical disease staging
CD4 count
ART
CD4 count (most recent and nadir)
HIV RNA load (most recent and highest)
Detail of ART regimen
Abbreviations: ALT, alanine aminotransferase; ART, antiretroviral therapy; AST, aspartate aminotransferase; BMRC, British Medical Research Council; CSF, cerebrospinal fluid; CT, computed 
tomography; FBC, full blood count; HIV, human immunodeficiency virus; IGRA, interferon-γ release assay; MRI, magnetic resonance imaging; NAAT, nucleic acid amplification test (including 
GeneXpert MTB/RIF); PCR, polymerase chain reaction; TB, tuberculosis; TBM, tuberculous meningitis; TST, tuberculin skin test; WBC, white blood cell; WHO, World Health Organization; 
ZN, Ziehl-Neelsen.
aData required for uniform TBM research case definition criteria (Table 2).
bClose/household contact with an infectious (pulmonary) TB case during the past year.
cThe yield of CSF ZN microscopy is so low that many laboratories do not offer this as a routine test.
dGenotypic (at least GeneXpert MTB/RIF) or phenotypic drug susceptibility testing must be performed if Mycobacterium tuberculosis is detected.
eAccording to modified BMRC criteria.
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MANAGEMENT AND MONITORING
Ensuring minimal standards of ancillary care and patient moni-
toring is essential for ethical reasons and for reporting purposes, 
as differences in local management practices are important 
confounders when assessing outcomes. Management and mon-
itoring protocols should be adequately described, including (1) 
antituberculosis drug treatment; (2) adjunctive anti-inflamma-
tory therapy; (3) management of hydrocephalus; and (4) other 
supportive care ( Table 3, Figure 1).
Antituberculosis Drug Treatment
As summarized in Table 3, it is essential to document the dose, 
route of administration, and duration of all antituberculosis 
drugs used in TBM treatment. Antituberculosis drug–related 
adverse events are more important in the treatment of TBM 
than other forms of tuberculosis because treatment interrup-
tions have been independently associated with death [24]. Drug-
induced liver injury (DILI) is the commonest adverse event and 
should be documented alongside changes in antituberculosis 
drug regimen. Outstanding questions remain concerning opti-
mal management when DILI occurs, and harmonized data col-
lection would allow analyses to address these.
When performing antituberculosis drug treatment trials, it is 
important to document drug quality as this can be highly var-
iable. WHO-prequalified drugs have been rigorously evaluated 
and meet strict quality criteria (a list of prequalified drugs is 
available at http://apps.who.int/prequal/query/ProductRegistry.
aspx). For other drugs, pharmaceutical companies should pro-
vide “certificates of analysis” and data on bioequivalence.
Pharmacokinetic/Pharmacodynamic Substudies
Pharmacokinetic/pharmacodynamic (PK/PD) substudies can 
help to explain trial findings and provide important dosing infor-
mation for future studies. Evaluation of individual exposures 
achieved provides insight into predictors of drug exposure and 
enables concentration-response relationships (PK/PD analysis) 
to be established [25–27]; the latter may reveal exposure thresh-
olds predictive of good treatment outcome or drug toxicity [26, 
28, 29]. Pharmacokinetic analysis should ideally include both 
plasma and CSF measurements, although CSF concentrations 
may not reflect the brain tissue concentration of highly lipo-
philic drugs [30, 31]. Pharmacokinetic studies often take place at 
“steady state,” when the processes of accumulation or induction 
are complete (in rifampicin this can take up to 10 days), but in 
TBM we suggest measuring exposures during the critical first 
days of treatment when mortality is highest [27]. CSF sampling 
after weeks of treatment may yield different results, as CSF drug 
penetration may reduce as meningeal inflammation lessens.
The standard method to assess CSF penetration is the CSF 
to plasma ratio for total drug exposure (area under the concen-
tration-time curve [AUC]) during the dosing interval, which 
requires multiple plasma and CSF samples [25]. Alternatively, 
a CSF to plasma concentration ratio can be established by a sin-
gle point measurement, but this is time dependent as the ratio 
is often variable over the dosing interval [31]. Although single 
time point CSF to plasma ratios should be interpreted with cau-
tion, pharmacokinetic modeling may approximate the CSF to 
plasma AUC ratio despite limited sampling, if such sampling 
takes place at multiple time points. It is important that CSF to 
plasma concentration ratios should be based upon estimated 
protein-unbound (“free”) exposure measures. In plasma, only 
the protein-unbound fraction is active and able to penetrate 
Table 2. Uniform Tuberculous Meningitis Research Case Definition 
Criteria[2]
Criteria
Clinical criteria (maximum category score = 6)
 Symptom duration of >5 d 4
 Systemic symptoms suggestive of TB (≥1): weight loss/(poor weight 
gain in children), night sweats, or persistent cough >2 wk
2
 History of recent close contact with an individual with pulmonary 
TB or a positive TST/IGRA in a child aged <10 y
2
 Focal neurological deficit (excluding cranial nerve palsies) 1
 Cranial nerve palsy 1
 Altered consciousness 1
CSF criteria (maximum category score = 4)
 Clear appearance 1
 Cells: 10–500/µL 1
 Lymphocytic predominance (>50%) 1
 Protein concentration >1 g/L 1
 CSF to plasma glucose ratio of <50% or an absolute CSF  
glucose concentration <2.2 mmol/L
1
Cerebral imaging criteria (maximum category score = 6)
 Hydrocephalus (CT and/or MRI) 1
 Basal meningeal enhancement (CT and/or MRI) 2
 Tuberculoma (CT and/or MRI) 2
 Infarct (CT and/or MRI) 1
 Precontrast basal hyperdensity (CT) 2
Evidence of tuberculosis elsewhere (maximum category score = 4)
 Chest radiograph suggestive of active TB (excludes miliary TB) 2
 Chest radiograph suggestive of miliary TB 4
 CT/MRI/US evidence for TB outside the CNS 2
 AFB identified or Mycobacterium tuberculosis cultured from 
another source (ie, sputum, lymph node, gastric washing, 
urine, blood culture)
4
 Positive commercial M. tuberculosis NAAT from extraneural 
specimen
4
Exclusion of alternative diagnoses: An alternative diagnosis must be  
confirmed microbiologically, serologically, or histopathologically.
Definite TBM: AFB seen on CSF microscopy, positive CSF M. tuberculosis 
culture, or positive CSF M. tuberculosis commercial NAAT in the setting 
of symptoms/signs suggestive of meningitis; or AFB seen in the context 
of histological changes consistent with TB brain or spinal cord together 
with suggestive symptoms/signs and CSF changes, or visible meningitis 
(on autopsy). 
Probable TBM: total score of ≥12 when neuroimaging available or  total score 
of ≥10 when neuroimaging unavailable. At least 2 points should either 
come from CSF or cerebral imaging criteria. 
Possible TBM: total score of 6–11 when neuroimaging available, or total 
score of 6–9 when neuroimaging unavailable.
Abbreviations: AFB, acid-fast bacilli; CNS, central nervous system; CSF, cerebrospinal fluid; 
CT, computed tomography; IGRA, interferon-γ release assay; MRI, magnetic resonance 
imaging; NAAT, nucleic acid amplification test; TB, tuberculosis; TBM, tuberculous meningi-
tis; TST, tuberculin skin test; US, ultrasound. 
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into the CSF. If a drug with high protein binding in plasma has 
excellent CSF penetration, a CSF to plasma ratio based on pro-
tein-unbound concentrations would be close to unity. In con-
trast, a ratio based on total (bound + unbound) concentrations 
would incorrectly suggest poor penetration [31], as is the case 
with rifampicin. Therefore, a correction for protein binding of 
plasma concentrations should always be made [25, 26].
Pharmacokinetic sampling can be “intensive” or “sparse,” 
or ideally a mixture of both to assist accurate modeling. 
Analytical methods used to determine drug concentrations 
should have appropriate intralaboratory (internal) assess-
ment of accuracy, precision, and other validation measures. 
Participation in an interlaboratory (external) proficiency 
testing program is recommended [32]. Of note, CSF drug 
concentrations cannot be measured using plasma assays 
without careful validation.
Adjunctive Anti-inflammatory Therapy
TBM studies should describe the type, dose, route of admin-
istration, and duration of anti-inflammatory therapy used 
(Table  3). Adjunctive corticosteroids are currently recom-
mended for all HIV-uninfected TBM patients during the first 
6–8 weeks of treatment [9]; they are also used in HIV-infected 
patients, although the evidence of benefit is much less clear. 
Corticosteroids are also often used for the management of 
tuberculomas and IRIS in HIV-infected patients, although the 
evidence base is weak. Some patients who do not respond to 
corticosteroids may benefit from other agents, such as thalido-
mide or anti–tumor necrosis factor-α biologic agents [33–36]. 
Two small studies also suggest that aspirin may reduce cerebral 
infarcts [37, 38], but this has not been confirmed in larger-scale 
studies.
Management of Hydrocephalus
As a minimum, the presence of hydrocephalus assessed 
by brain CT or MRI should be documented at the start of 
treatment. An assessment of whether the hydrocephalus is 
communicating or noncommunicating is desirable, and the 
management (medical or surgical) should be documented 
(Table 3). Raised intracranial pressure, largely due to hydro-
cephalus, is a common problem in patients with TBM [10, 
39]. If untreated, hydrocephalus can exacerbate the cerebral 
ischemia caused by perfusion-limiting vasculitis, which is a 
key feature of TBM. Untreated hydrocephalus is independently 
associated with death [40, 41]. Whether the hydrocephalus is 
communicating or noncommunicating [10, 42] has important 
management implications. At present, the only way to relia-
bly differentiate communicating from noncommunicating 
Table 3. Data Collection Requirements for Patient Management and Monitoring in Tuberculous Meningitis Studies
Requirements Essential Desirable
Management TB treatment
 Initiation date
 Drug doses and route of administration
 Treatment duration and adherence
Anti-inflammatory treatment
 Corticosteroids and/or other anti-inflammatory agents 
(type, dose, duration)
Hydrocephalus management
 Medical (drugs, dose, duration)
 Surgical (shunt type)
ART
 Initiation date (if new)
 Regimen used
 Treatment adherence
 Time from TBM treatment to ART initiation
TB treatment–related adverse events (especially drug-induced liver injury)
Surgery-related adverse events
Description of adverse events
Time to shunt
ART-related adverse effects
Treatment interruptions (number, total duration)
Monitoring Observationsa
 Level of consciousness
 Change in TBM severity grade (day 7)
Blood testsc
 Full blood count
 Serum sodium, potassium, urea, and creatinine
 Liver aminotransferases (ALT, AST)
CSF b
 Opening pressure; cell count and differential; protein, glucose;  
Ziehl-Neelsen stain; and mycobacterial culture and DST
 During acute illnessa record lowest blood pressure, pulse oximetry, blood 
glucose
If admitted to ICU
 Blood gas; continuous intracranial pressure and cerebral oxygenation/ 
perfusion monitoring
If HIV infected
 CD4 T-cell count at 3, 6, and 12 months
 HIV RNA load at 6 and 12 months
 Abbreviations: ALT, alanine aminotransferase; ART, antiretroviral therapy; AST, aspartate aminotransferase; CSF, cerebrospinal fluid; DST, drug susceptibility testing; HIV, human immunode-
ficiency virus; ICU, intensive care unit; TB, tuberculosis; TBM, tuberculous meningitis.
aAt a minimum, clinical observations should be performed daily during the first 7 days, weekly during the first month, and monthly during the first 6 months.
bIf the diagnosis of TBM is uncertain, it is recommended to repeat CSF analysis 3–7 days after the start of treatment. Otherwise, CSF after 30 and 60 days of treatment can help to 
assess treatment response and likelihood of drug resistance.
cAs a minimum, blood tests should be performed at diagnosis, weekly during the first month, and monthly during the first 6 months.
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hydrocephalus is with an air encephalogram or using contrast 
ventriculography [43, 44]. Performing an air encephalogram 
does not require any special resources and can be performed 
when collecting a CSF sample. Ventricular shunting is usu-
ally indicated for noncommunicating hydrocephalus, while a 
combination of diuretics (acetazolamide and furosemide) may 
treat communicating hydrocephalus [45]; the value of this 
approach requires further confirmation in adults.
General Supportive Care
The provision of optimal supportive care in patients with TBM 
is rarely reported and often neglected and is therefore high-
lighted here. Hyponatremia occurs in a high percentage of TBM 
patients, is associated with poorer outcome [10], and should be 
documented (Table 3). Hyponatremia may result from inappro-
priate antidiuretic hormone secretion or cerebral salt wasting 
or may represent an appropriate compensatory response to 
maintain cerebral perfusion. Plasma sodium concentrations 
should be recorded at baseline and through the early phase 
of hospital treatment. In critically ill patients, changes in cer-
ebral perfusion and oxygenation are highly dynamic, but can 
be captured through continuous intracranial monitoring. This 
is invasive and only possible during intensive care admission in 
settings where such facilities exist. Transcranial Doppler [46] 
and near-infrared spectroscopy provide less-invasive alterna-
tives, but these methods require more rigorous validation and 
have not yet demonstrated clinical utility. Simple measures to 
reduce cerebral ischemia and brain cell metabolic stress include 
maintaining adequate blood pressure and glucose levels, pro-
viding supplemental oxygen, and controlling fever [47]. These 
parameters should be recorded in all critically ill patients 
(Table 3).
OUTCOME MEASURES
The inconsistent reporting of outcome measures limits crit-
ical study evaluation and comparison. TBM is associated with 
high mortality; therefore, death is an essential outcome meas-
ure. The time of death in relation to the start of antituberculo-
sis treatment should also be documented, and we recommend 
reporting to at least 12 months from antituberculosis treatment 
initiation. Cause of death is notoriously difficult to determine 
without formal postmortem examination, but deaths dir-
ectly attributable to TBM are more likely to occur in the first 
3 months of treatment; later deaths may be caused by secondary 
infections, for example, especially in those left with severe neu-
rological disability. An assessment by the attending physician as 
to the likely cause of death (TBM attributable/not attributable) 
is desirable but not essential, given the inherent limitations of 
this approach.
The reporting of functional outcomes are also essential, 
but different measures are used [9], and detailed neurocogni-
tive outcomes are rarely assessed [48]. Given the importance 
of neurodisability and comparable outcome measurement, 
we recommend that the Modified Rankin Score should be 
recorded 12  months from antituberculosis treatment initi-
ation in all adults and in children. The score (detailed in the 
Supplementary Appendix) assesses whether or not the subject 
can live independently of others. We also recommend recording 
the Pediatric Version of the Glasgow Outcome Scale–Extended 
(GOS-E peds) in children (Table 4); however, this scale, created 
for children following neurotrauma, needs further validation in 
childhood TBM.
TBM causes significant long-term neurocognitive impair-
ment in children [10, 49] and adults [7], and detailed neuro-
cognitive and psychiatric outcomes should be reported where 
possible. The Griffiths Mental Developmental Scales or the 
Pediatric Cerebral Performance Category Scale provide assess-
ment on age-appropriate neurocognitive and developmental 
At presentation / Diagnosis 
• Demographics, medical history, presenting symptoms and 
signs
• Cerebrospinal fluid analysis and mycobacterial culture & DST
• Other laboratory investigations (LFTs), brain imaging (Table 1)
• Assess diagnostic certainty (Table 2) & BMRC severity grade 
(Figure 2)
• HIV test all; if infected: CD4 count, viral load, ART
During the first month  
• Day 7 BMRC TBM severity grade
• Conscious level and new neurological events (Table 3)
• Anti-TB drug treatment, anti-inflammatory treatment, 
hydrocephalus management, ART (Table 3)
• Relevant blood tests as required (at least once/week)
• Cerebrospinal fluid analysis if diagnostic uncertainty/poor 
treatment response
• Serious adverse events
Beyond the first month 
• New neurological events (Table 3)
• Anti-TB treatment, anti-inflammatory treatment, hydrocephalus 
management, ART (Table 3)
• Monthly conscious level
• Relevant blood tests as required (at least once/month)
• Serious adverse events
12 months from TB treatment initiation 
• Death and disability (Table 4)
• Time to hospital discharge
• New neurological events
• Serious adverse events
• For HIV-infected patients: new stage 4 illnesses, TBM-IRIS
Figure  1. Proposed minimum schedule of investigations and outcome meas-
urements in studies of tuberculous meningitis. Abbreviations: ART, antiretroviral 
therapy; BMRC, British Medical Research Council; DST, drug susceptibility testing; 
HIV, human immunodeficiency virus; IRIS, immune reconstitution inflammatory syn-
drome; LFTs, liver function tests; TBM, tuberculous meningitis.
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outcomes. It is important that children are compared to age-
matched controls from the same socioeconomic background, 
given major environmental influences on early cognitive 
development.
Paradoxical Reactions
Clinical deterioration after the start of antituberculosis treat-
ment—commonly called paradoxical reactions and asso-
ciated with increased intracerebral inflammation—occurs 
in approximately 30% of HIV-uninfected individuals with 
TBM [50] and around 50% of those who are HIV infected 
[14]. Paradoxical reactions are associated with new or wors-
ening intracerebral tuberculomas, hydrocephalus, infarcts, 
and/or spinal radiculomyelitis. In HIV-infected subjects 
recently started on antiretroviral therapy, these events may 
be defined as TBM- IRIS following the International Network 
for the Study of HIV-Associated IRIS criteria [51], modified 
for TBM.
All suspected paradoxical reactions and their timing with 
respect to antituberculosis drug initiation should be recorded 
(Table  4). When possible, providers should investigate all 
suspected paradoxical reactions with brain imaging and 
document the findings, management given, and outcomes. 
Alternative causes that should be excluded as far as possi-
ble include drug resistance, poor adherence to treatment, 
drug-related adverse events, and other opportunistic infec-
tions. We also recommend that all WHO HIV stage 4 illnesses 
should be recorded throughout the course of TBM treatment 
(Table 4).
PROPOSED CORE DATASET
Participants at the workshop reinforced calls for standardized 
approaches, including laboratory and clinical assessment proce-
dures and data reporting. All laboratory tests should be guided 
by detailed standard operating procedures, including sample 
collection, processing, transport, storage, and laboratory pro-
cedures for specific diagnostic tests, including quality assurance 
measures; relevant standard operating procedures are included 
in the Supplementary Data. Demographic and clinical data 
should also be collected in a standardized fashion. The essential 
elements listed in the tables provide the basis for a core data-
set that represents the minimum data to be captured in future 
TBM studies. A proposed data capture form that includes all 
the proposed “essential” and “desirable” variables (Tables 1–4) 
is included in the Supplementary Data.
CONCLUSIONS
Developing standardized approaches represents a critical first 
step to establish the evidence base required to improve TBM 
detection and outcome. Poor study comparability due to varia-
ble methods, case definitions, and data collection and reporting 
highlight the inadequacy of current approaches. Wide adoption 
of the standard methods proposed here should help to move 
the field forward and ensure that the benefits of technological 
advances are fully realized. This document should be viewed as 
a living tool that will be refined as the evidence base and field 
experience with conducting multicenter TBM studies grow and 
are critically evaluated at future meetings.
Table 4. Primary and Secondary Outcome Measures to Be Reported in Tuberculous Meningitis Studies
All Patients Essential Desirable
Primary outcomes
(assessed 12 mo from start of  
anti-TB treatment)
Death; time to death
Neurological disabilitya
Cause of deathb
Detailed neurocognitive and behavioral outcomes
Secondary outcomes Coma clearancec; time to event
New neurological eventd; time to event
Change in TBM severity grade by day 7 of anti-TB treatment
Coma management
Radiological findings (brain imaging) investigating 
new neurological event
All serious adverse eventse and their relationship to the disease 
or drugs given
Anti-TB drug treatment interruptions (number, total 
duration)
Time to event; likely causative agent; management
Complications related to corticosteroid therapy
Time to hospital discharge Admission to ICU; duration of admission
Requires mechanical ventilation; duration of 
ventilation
HIV-infected patients
 New stage 4 illnesses Nature of condition; time to event Management of condition
 Neurological TB-IRIS Nature of condition; time to event
Report TB-IRIS criteria used
Management of condition
Abbreviations: HIV, human immunodeficiency virus; ICU, intensive care unit; IRIS, immune reconstitution inflammatory syndrome; TB, tuberculosis; TBM, tuberculous meningitis.
aUse Modified Rankin Score in adults and children, and the GOS-E (pediatric version of the Glasgow Outcome Scale–Extended) score in children (see Supplementary Data for scoring criteria).
bCause of death should be reported as TBM attributable or not attributable (determined by postmortem and/or clinical records).
cFrom TBM treatment initiation until Glasgow Coma Scale (GCS) score of 15 for 2 consecutive days.
dDefined as a fall in GCS of ≥2 points for ≥48 hours, new focal neurological sign, or new onset of seizures.
eAny adverse event, adverse reaction, or unexpected adverse reaction that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in 
persistent or significant disability or incapacity, or consists of a congenital anomaly or birth defect.
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Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the author to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the author, so 
questions or comments should be addressed to the author.
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